Dr. van Vollenhoven has received consultant fees, speaking fees, honoraria, and/or research grants (less than $10,000 each) from Abbott Pharmaceuticals, Bristol-Myers Squibb, Centocor, Roche, Wyeth, and Schering-Plough.
Improvement in work place and household productivity for patients with early rheumatoid arthritis treated with adalimumab plus methotrexate: Work outcomes and their correlations with clinical and radiographic measures from a randomized controlled trial companion study
Article first published online: 28 JAN 2010
Copyright © 2010 by the American College of Rheumatology
Arthritis Care & Research
Volume 62, Issue 2, pages 226–234, February 2010
How to Cite
van Vollenhoven, R. F., Cifaldi, M. A., Ray, S., Chen, N. and Weisman, M. H. (2010), Improvement in work place and household productivity for patients with early rheumatoid arthritis treated with adalimumab plus methotrexate: Work outcomes and their correlations with clinical and radiographic measures from a randomized controlled trial companion study. Arthritis Care Res, 62: 226–234. doi: 10.1002/acr.20072
- Issue published online: 28 JAN 2010
- Article first published online: 28 JAN 2010
- Manuscript Accepted: 21 SEP 2009
- Manuscript Received: 23 DEC 2008
- Abbott Laboratories
To evaluate household and work place outcomes for patients with rheumatoid arthritis (RA) who were homemakers or employed workers, respectively, and who were treated with adalimumab plus methotrexate versus methotrexate monotherapy. We also determined baseline predictors of household and work place outcomes.
Data were from a health economic companion study to PREMIER, a 2-year, randomized controlled trial of methotrexate-naive patients with early RA (<3 years) who received treatment with adalimumab plus methotrexate, adalimumab, or methotrexate. Absenteeism (number of days missed or unfit to work), presenteeism (self-judgment of the effects of RA on job or household performance), and employment status were collected from self-reports at baseline and varying time points during the study.
Household and work place outcomes were generally similar for homemakers and employed workers. Over 2 years, patients who received combination therapy missed approximately half as many days as patients who received methotrexate (17.4 versus 36.9 days for employed workers; 7.9 versus 18.6 days for homemakers). Presenteeism was lower (reflecting better productivity) for combination therapy than methotrexate monotherapy. The likelihood of gaining/retaining employment over 2 years was greater for combination therapy than methotrexate monotherapy (odds ratio 1.530, 95% confidence interval 1.038–2.255; P = 0.0318). Baseline radiographic progression was an independent predictor for retaining/gaining employment at 2 years.
Compared with methotrexate monotherapy, combination therapy was associated with more positive work outcomes: less absenteeism, less presenteeism, and greater likelihood of gaining/retaining employment. Radiographic progression at baseline was predictive of the ability to retain or gain employment.